Pfizer Forges Research Partnership In China Aimed At Fighting Cancers Prevalent In Asia
This article was originally published in The Pink Sheet Daily
Executive Summary
Scientists from Pfizer and Crown Bioscience join forces to research and develop novel treatments, including therapeutics to combat liver cancer, the second leading cause of cancer death in China.
You may also be interested in...
As Merger With Wyeth Hangs In The Balance Of Beijing's Hands, Pfizer CEO Tours China To Launch Scholarly Partnerships
BEIJING - With the fate of a $68-billion merger with Wyeth now being reviewed by the Chinese leadership, Pfizer Chief Executive Officer Jeff Kindler is on a five-day, whirlwind tour of the country, in part to launch a new wave of partnerships with scientists and scholars
Bristol-Myers Squibb Foundation Donates Funds For Hepatitis Awareness, Prevention In China
BEIJING - Aimed at combating a leading cause of death in the world's most populous nation, the Bristol-Myers Squibb Foundation is setting up partnerships with public health groups across China to promote awareness and prevention of hepatitis
Pfizer Head of R&D Business Development-Asia Alex Fowkes On Developing R&D Strategies For Asia: An Interview With PharmAsia News (Part 1 of 2)
Pfizer Head of R&D Business Development-Asia Alex Fowkes sat down recently with PharmAsia News' Australia bureau to discuss Pfizer's research and business development strategies in Asia. Fowkes recently addressed a panel at the BioAsia conference in Singapore and discussed Pfizer's virtual networking approach to doing business in Asia, which offers more flexibility and creative approaches (PharmAsia News, May 8, 2008).